Senses Disorder TRIZ Cases

Targeting Annexin-A1 with a monoclonal antibody inhibits T cell activation, reducing inflammatory responses without adverse cytotoxic effects.

Intravitreal AAV8 vectors bypass subretinal injection risks by diffusing through the vitreous humor to achieve widespread retinal transduction.

FLT4-binding peptide directs nanocarriers to Schlemm's canal endothelial cells, reducing intraocular pressure while minimizing off-target effects.

Modifying molecular parameters of bicyclic heteroaryl compounds enhances blood-brain barrier penetration to treat neuropsychiatric disorders.

Tricyclic compounds capture reactive carbonyl species via nucleophilic addition, reducing cytotoxicity and tissue damage in disease treatment.

Targeting the SOX21 pathway mitigates glaucomatous optic nerve degradation by lowering intraocular pressure.

Bridged bicyclic triazole compounds inhibit the Axl receptor protein tyrosine kinase to treat solid tumors and vascular diseases.

HYPDX-4 replaces invasive electrodes with non-invasive optical sensing, enabling real-time imaging of retinal oxygen levels.

A substituted indole benzylamine compound inhibits tryptase activity through specific fluoro and methoxyethyl group placements.

A fibromodulin-containing culture medium reprograms mammalian cells into pluripotent stem cell-like clones without feeder layers.

A piperazine-based FAAH modulator structure delivers potent enzyme inhibition with reduced sedation.

Packaging SaCas9 and homology-directed repair templates into a single AAV vector reduces delivery complexity while maintaining high editing reliability.

Engineered mutant opsin and arrestin variants accelerate deactivation kinetics to improve signal precision.

Composite berberine and ursodeoxycholic acid salts treat metabolic disorders by reducing blood glucose while minimizing side effects.

Segmented Gas6-LamininG peptides maintain biological stability during sustained-release delivery, resolving inactivation issues of full-length proteins.

Dual-functional compounds covalently link nitrogen mustards with CDK inhibitors to prevent DNA repair and overcome drug resistance.

Segmented Class 2 Type V CRISPR components delivered via AAV vectors correct P23H rhodopsin mutations, addressing delivery complexity barriers.

CTRP6 targets the complement alternative pathway to treat autoimmune diseases by selectively inhibiting C3 activation without affecting classical pathways.

Compound 1 reduces retinal cytotoxic bisretinoids by inhibiting the visual cycle, addressing the lack of dry AMD therapies.

6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazin-6-yl derivatives inhibit beta-secretase enzymes to block amyloid peptide generation.

Substituted sulfonamide compounds inhibit TRPA1 channels, resolving the trade-off between therapeutic effectiveness and adverse effects in pain treatment.

PEGylated polypeptides resolve half-life trade-offs by resisting enzymatic degradation while maintaining therapeutic efficacy against fibrotic lesions.

Supplying synthetic peptides with specific signal motifs adjusts the balance between type 1 and type 2 TNF receptors to modulate physiological effects.

Refrigerating phenylephrine hydrochloride with an aqueous buffer prevents racemization and discoloration, maintaining therapeutic potency for six months.

Isoquinoline sulfonamide derivatives modify molecular structure to enhance solubility and pharmacokinetics while maintaining Rho kinase inhibitory activity.

Novel ENaC blockers remove amino substituents from pyrazine rings to extend duration of action while minimizing renal side effects.

C-15 thiazole derivatives with methyl side chains selectively inhibit 17β-HSD1 while improving metabolic stability and minimizing impact on 17β-HSD2.

Selective pyrazoloquinolinone ligands allosterically modulate alpha-6 GABAA receptors, resolving the toxicity trade-off of direct channel openers.

Thienyl glycopyranosyl derivatives inhibit intestinal and renal sodium-dependent glucose transporters to lower blood glucose levels.

Iontophoresis drives riboflavin into the corneal stroma via electrical current, eliminating epithelial removal and anesthesia requirements.

Small molecule fused pentacyclic imidazoles resolve the trade-off between macromolecular complexity and structural diversity in TNFα inhibition.

Compounds correct protein folding defects and restore ion balance by modifying pyridine ring structures.

Replacing natural protease sites with specific substrates allows self-activation, eliminating external enzyme dependency and improving yield.

Orexin antagonists reduce intraocular pressure fluctuations by blocking neurophysiologic pathways, preventing optic nerve damage.

Bees process a cannabis-infused food base into honey, creating a safe medical product with lower active ingredient concentrations.

A dye composition combining Trypan Blue with specific additives to enhance staining efficiency of retinal membranes.

Electroporation devices transfer nucleic acids into ciliary body tissue for targeted ocular therapy.

Substituted phenylamino isonicotinamide compounds inhibit MEK activity through targeted structural modifications.

Pharmaceutical compositions upregulate Atoh1 expression to drive epithelial cell differentiation into functional auditory hair cells.

Sulfonyl-phenyl-oxadiazolone compounds merge PPAR delta and alpha agonism to resolve variable efficacy in lipid metabolism treatment.

Biocompatible polymer matrix releases siRNA complexes to overcome low bioavailability and transient gene knockdown in ocular treatments.

A bicyclic compound inhibits acetyl-CoA carboxylase to treat cancer and inflammatory diseases.

Spirocyclic compounds inhibit DGAT1 while improving pharmacokinetic properties for clinical advancement.

A fusion polypeptide combines a fynomer and antibody to bind IL-17a and IL-6R simultaneously.

Modified chemical structures enhance oral bioavailability while reducing toxic side effects compared to existing Fasudil treatments.

Topical TRPA1 channel antagonist compounds protect retinal tissue from oxidative stress, avoiding invasive procedures and severe side effects.

6-aminoisoquinoline compounds inhibit kinases to prevent receptor desensitization and sustain therapeutic effectiveness.

Heteroaromatic compounds inhibit IL-17 secretion by targeting RORgamma, addressing limited therapeutic options in autoimmune disease management.

High-affinity Epo antibodies bind erythropoietin to block cell proliferation and signaling pathways.